Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 11;8(3):FSO784.
doi: 10.2144/fsoa-2022-0002. eCollection 2022 Mar.

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy

Giuseppe Di Lorenzo  1   2   3 , Luca Scafuri  1   2 , Ferdinando Costabile  1   2 , Liuba Pepe  3 , Anna Scognamiglio  3 , Felice Crocetto  4 , Germano Guerra  3 , Carlo Buonerba  1   2
Affiliations
Editorial

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy

Giuseppe Di Lorenzo et al. Future Sci OA. .
No abstract available

Keywords: androgen deprivation therapy; fisetin; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References

    1. Worldwide cancer data. (2021). https://www.wcrf.org/dietandcancer/worldwide-cancer-data
    1. Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr. Drug Targets 13, 1676–1686 (2012). - PubMed
    1. Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019). - PubMed
    1. Ferro M, Lucarelli G, Crocetto F et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol. 157, 103198 (2021). - PubMed
    1. Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer. Curr. Oncol. 28, 3331–3346 (2021). - PMC - PubMed

Publication types

LinkOut - more resources